Can molecular stratification improve the treatment of inflammatory bowel disease?

Wang, C., Baer, H. M., Gaya, D. R., Nibbs, R. J.B. and Milling, S. (2019) Can molecular stratification improve the treatment of inflammatory bowel disease? Pharmacological Research, 148, 104442. (doi: 10.1016/j.phrs.2019.104442) (PMID:31491469) (PMCID:PMC6902263)

197092.pdf - Published Version
Available under License Creative Commons Attribution.



Inflammatory bowel disease (IBD) is a debilitating chronic inflammatory disease of the gastrointestinal (GI) tract. It affects more than 3.5 million people in the western world and places a huge financial burden on healthcare systems. IBD is highly heterogeneous; disease severity and outcomes in IBD are highly variable, and patients may experience episodes of relapse and remission. However, treatment often follows a step-up model whereby the patients start with anti-inflammatory agents (corticosteroids or immunosuppressants) and step-up to monoclonal anti-tumour necrosis factor-α (TNFα) antibodies and then other biologics if the initial drugs cannot control disease. Unfortunately, many patients do not respond to the costly biologics, and thus often still require gut-resective surgery, which decreases quality of life. In order to decrease rates of surgery and ineffective treatments, it is important to identify markers that accurately predict disease progression and treatment responses, to inform decisions about the best choice of therapeutics. Here we examine molecular approaches to patient stratification that aim to increase the effectiveness of treatments and potentially reduce healthcare costs. In the future, it may become possible to stratify patients based on their suitability for specific molecular-targeted therapeutic agents, and eventually use molecular stratification for personalised medicine in IBD.

Item Type:Articles
Keywords:Anti-TNF, biologics, CD, Crohn’s disease, disease stratification, faecal calprotectin, genomics, inflammatory bowel disease, microbiomics, molecular stratification, precision medicine, proteomics, serological markers, transcriptomics, treatment response, UC, ulcerative colitis.
Glasgow Author(s) Enlighten ID:Milling, Professor Simon and Baer, Hannah and Gaya, Mr Daniel and Nibbs, Professor Rob
Authors: Wang, C., Baer, H. M., Gaya, D. R., Nibbs, R. J.B., and Milling, S.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Pharmacological Research
ISSN (Online):1096-1186
Published Online:03 September 2019
Copyright Holders:Copyright © 2019 The Authors
First Published:First published in Pharmacological Research 148: 104442
Publisher Policy:Reproduced under a Creative Commons Licence

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
304005MRC Precision Medicine Training GrantMorven BarlassMedical Research Council (MRC)MR/N013166/1-LGH/MS/MED25CAMS - Cardiovascular Science